Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)

[1]  G. Guida,et al.  The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. , 2003, Blood.

[2]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[3]  C. Hertel,et al.  PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. , 2002, Cellular signalling.

[4]  L. Bullinger,et al.  Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course , 2002, Leukemia.

[5]  K. Metze,et al.  Spontaneous apoptosis in chronic lymphocytic leukemia and its relationship to clinical and cell kinetic parameters. , 2001, Cytometry.

[6]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[7]  C. Reutelingsperger,et al.  Flow cytometry of apoptotic cell death. , 2000, Journal of immunological methods.

[8]  S. Zhao,et al.  Cell-surface exposure of phosphatidylserine correlates with the stage of fludarabine-induced apoptosis in chronic lymphocytic leukemia and expression of apoptosis-regulating genes. , 2000, Cytometry.

[9]  S. Basu,et al.  Theophylline as a therapy for chronic lymphocytic leukemia: a case report and review of literature. , 2000, Haematologia.

[10]  C. Pepper,et al.  Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation. , 1999, Leukemia research.

[11]  R. Muñoz,et al.  Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. , 1999, Cytometry.

[12]  A. G. Bosanquet,et al.  CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase. , 1999, Cytometry.

[13]  D. Makower,et al.  Therapeutic efficacy of theophylline in chronic lymphocytic leukemia , 1999, Medical oncology.

[14]  M. Tomonaga,et al.  Qualitative and quantitative characterization of Fas (APO-1/CD95) on leukemic cells derived from patients with B-cell neoplasms. , 1999, Leukemia research.

[15]  F. Mentz,et al.  Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production , 1999, Leukemia.

[16]  A. Lerner,et al.  Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. , 1998, Blood.

[17]  M. Ormerod.  The study of apoptotic cells by flow cytometry , 1998, Leukemia.

[18]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[19]  M. Andreeff,et al.  Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. , 1998, Blood.

[20]  John Calvin Reed.  Chronic lymphocytic leukemia: A disease of dysregulated programmed cell death* , 1997 .

[21]  W. Dalton,et al.  Selection for drug resistance results in resistance to Fas-mediated apoptosis. , 1997, Blood.

[22]  C. Pepper,et al.  REGULATION OF CLINICAL CHEMORESISTANCE BY bcl‐2 AND BAX ONCOPROTEINS IN B‐CELL CHRONIC LYMPHOCYTIC LEUKAEMIA , 1996, British journal of haematology.

[23]  F. Mentz,et al.  Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. , 1996, Blood.

[24]  S. Zupo,et al.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. , 1996, Blood.

[25]  S. Korsmeyer,et al.  Molecular thanatopsis: a discourse on the BCL2 family and cell death. , 1996, Blood.

[26]  M. Rottenberg,et al.  Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progression , 1996, International journal of cancer.

[27]  T. McDonnell,et al.  Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. , 1996, Journal of immunology.

[28]  John Calvin Reed,et al.  Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. , 1996, Oncogene.

[29]  C. Page,et al.  Anti‐inflammatory effects of theophylline and selective phosphodiesterase inhibitors , 1996 .

[30]  C. Page,et al.  Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. , 1996, The European respiratory journal.

[31]  K. Chung,et al.  Theophylline in chronic asthma–evidence for disease‐modifying properties , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[32]  F. Mentz,et al.  Synergistic action of alkylating agents and methylxanthine derivatives in the treatment of chronic lymphocytic leukemia. , 1995, Leukemia.

[33]  F. Ouaaz,et al.  Theophylline, a new inducer of apoptosis in B‐CLL: role of cyclic nucleotides , 1995, British journal of haematology.

[34]  K. Chung,et al.  Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. , 1995, American journal of respiratory and critical care medicine.

[35]  E. Smeland,et al.  TGF-beta 1 and cyclic AMP promote apoptosis in resting human B lymphocytes. , 1995, Journal of immunology.

[36]  A. Modica,et al.  Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method. , 1994, Blood.

[37]  E. Montserrat,et al.  5th International Workshop on Chronic Lymphocytic Leukemia. , 1992, Leukemia research.

[38]  S. Orrenius,et al.  Agents that elevate cAMP stimulate DNA fragmentation in thymocytes. , 1990, Journal of immunology.

[39]  T. Rall.  Drugs used in the treatment of asthma , 1990 .

[40]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[41]  G. Canonica,et al.  Theophylline and the immune response: in vitro and in vivo effects. , 1988, Clinical immunology and immunopathology.

[42]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[43]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .